AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1
Not Quite At The Summit But Tremelimumab Hits A High
Executive Summary
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.
You may also be interested in...
AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.